FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981993097> ?p ?o ?g. }

• W2981993097 endingPage "S654" @default.
• W2981993097 startingPage "S654" @default.
• W2981993097 abstract "Recent advances in detection of genomic DNA from plasma samples allow us to follow the alteration of shedding tumor DNA in plasma before and after systemic treatment with multiple biopsies. Osimertinib is the standard of care for NSCLC patients with T790M mutations. We plan to use serial plasma cfDNA genomic alteration to predict osimertinib efficacy and search for possible resistance mechanisms. We prospectively collected plasma from patients of EGFR mutation-positive NSCLC who harbored acquired EGFR T790M mutation following prior EGFR-TKI therapy. Plasma samples were collected before starting osimertinib treatment, 4 weeks following osimertinib treatment and upon disease progression. ctDNA were detected by Guardant360 gene panel test. Fifteen patients (median age 62 [range 48-77], 53% men, 53% exon 19 deletion and 47% exon 21 L858R mutation) received osimertinib treatment. Acquired T790M mutation was diagnosed by using plasma sample only (Cobas® or digital PCR) (n = 11), tissue or pleural effusion only (n = 2), and both tissue and plasma samples (n = 2). Before starting osimertinib treatment, activating mutations were detected in plasma in all patients, T790M was detected in 93% (n = 14) and TP53 mutation was detected in 47% (n = 7) of the patients by using Guardant360. After osimertinib treatment, 11 out of the 14 patients had non-detectable plasma T790M at the 4th week. Follow-up CT at least 8 weeks following osimertinib treatment of the 11 patients disclosed decreased tumor size (6 confirmed PR, 1 unconfirmed PR and 5 SD by RECIST criteria). The remaining 3 patients who had detectable plasma T790M (n = 2) or increased activating mutation allele frequency (n = 1) at the 4th week had progressive disease within 16 weeks. The first patient had initial PR but later developed C797S on progression. The second patient developed new liver tumor following prior stable disease. This patient had baseline TP53 and CDKN2A mutations detected in the plasma, and allele frequencies decreased at the 4th week and increased on progression. The last patient had rapid progression on osimertinib treatment, and alterations in PTEN and TP53 were detected on baseline and increased at the 4th week and on progression. In that patient, T790M mutation was not detectable at the 4th week but activating mutation increased in allele frequency at the 4th week and on progression. Regarding patients with baseline TP53 mutation, 4 (57%) patients who had non-detectable plasma TP53 mutation at the 4th week achieved disease control, and 2 (29%) patients had detectable or increased TP53 mutation allele frequency had PD within 16 weeks. 4 week plasma ctDNA following osimertinib treatment may predict early progression within 16 weeks." @default.
• W2981993097 created "2019-11-01" @default.
• W2981993097 creator A5009000893 @default.
• W2981993097 creator A5013389671 @default.
• W2981993097 creator A5036505444 @default.
• W2981993097 creator A5043008228 @default.
• W2981993097 creator A5048965137 @default.
• W2981993097 creator A5055415475 @default.
• W2981993097 creator A5063270835 @default.
• W2981993097 creator A5065419718 @default.
• W2981993097 creator A5068475432 @default.
• W2981993097 creator A5077112170 @default.
• W2981993097 creator A5084397879 @default.
• W2981993097 date "2019-10-01" @default.
• W2981993097 modified "2023-10-18" @default.
• W2981993097 title "P2.01-39 Serial Plasma ctDNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M+ NSCLC" @default.
• W2981993097 doi "https://doi.org/10.1016/j.jtho.2019.08.1383" @default.
• W2981993097 hasPublicationYear "2019" @default.
• W2981993097 type Work @default.
• W2981993097 sameAs 2981993097 @default.
• W2981993097 citedByCount "0" @default.
• W2981993097 crossrefType "journal-article" @default.
• W2981993097 hasAuthorship W2981993097A5009000893 @default.
• W2981993097 hasAuthorship W2981993097A5013389671 @default.
• W2981993097 hasAuthorship W2981993097A5036505444 @default.
• W2981993097 hasAuthorship W2981993097A5043008228 @default.
• W2981993097 hasAuthorship W2981993097A5048965137 @default.
• W2981993097 hasAuthorship W2981993097A5055415475 @default.
• W2981993097 hasAuthorship W2981993097A5063270835 @default.
• W2981993097 hasAuthorship W2981993097A5065419718 @default.
• W2981993097 hasAuthorship W2981993097A5068475432 @default.
• W2981993097 hasAuthorship W2981993097A5077112170 @default.
• W2981993097 hasAuthorship W2981993097A5084397879 @default.
• W2981993097 hasBestOaLocation W29819930971 @default.
• W2981993097 hasConcept C104317684 @default.
• W2981993097 hasConcept C121608353 @default.
• W2981993097 hasConcept C126322002 @default.
• W2981993097 hasConcept C142724271 @default.
• W2981993097 hasConcept C143998085 @default.
• W2981993097 hasConcept C2775999482 @default.
• W2981993097 hasConcept C2777626846 @default.
• W2981993097 hasConcept C2777930144 @default.
• W2981993097 hasConcept C2778087573 @default.
• W2981993097 hasConcept C2779438470 @default.
• W2981993097 hasConcept C2781182431 @default.
• W2981993097 hasConcept C501734568 @default.
• W2981993097 hasConcept C54355233 @default.
• W2981993097 hasConcept C71924100 @default.
• W2981993097 hasConcept C86803240 @default.
• W2981993097 hasConceptScore W2981993097C104317684 @default.
• W2981993097 hasConceptScore W2981993097C121608353 @default.
• W2981993097 hasConceptScore W2981993097C126322002 @default.
• W2981993097 hasConceptScore W2981993097C142724271 @default.
• W2981993097 hasConceptScore W2981993097C143998085 @default.
• W2981993097 hasConceptScore W2981993097C2775999482 @default.
• W2981993097 hasConceptScore W2981993097C2777626846 @default.
• W2981993097 hasConceptScore W2981993097C2777930144 @default.
• W2981993097 hasConceptScore W2981993097C2778087573 @default.
• W2981993097 hasConceptScore W2981993097C2779438470 @default.
• W2981993097 hasConceptScore W2981993097C2781182431 @default.
• W2981993097 hasConceptScore W2981993097C501734568 @default.
• W2981993097 hasConceptScore W2981993097C54355233 @default.
• W2981993097 hasConceptScore W2981993097C71924100 @default.
• W2981993097 hasConceptScore W2981993097C86803240 @default.
• W2981993097 hasIssue "10" @default.
• W2981993097 hasLocation W29819930971 @default.
• W2981993097 hasOpenAccess W2981993097 @default.
• W2981993097 hasPrimaryLocation W29819930971 @default.
• W2981993097 hasRelatedWork W2569056264 @default.
• W2981993097 hasRelatedWork W2735114053 @default.
• W2981993097 hasRelatedWork W2761796664 @default.
• W2981993097 hasRelatedWork W2896568882 @default.
• W2981993097 hasRelatedWork W2909704566 @default.
• W2981993097 hasRelatedWork W3135851905 @default.
• W2981993097 hasRelatedWork W4207054516 @default.
• W2981993097 hasRelatedWork W4245657304 @default.
• W2981993097 hasRelatedWork W4281911250 @default.
• W2981993097 hasRelatedWork W4318323499 @default.
• W2981993097 hasVolume "14" @default.
• W2981993097 isParatext "false" @default.
• W2981993097 isRetracted "false" @default.
• W2981993097 magId "2981993097" @default.
• W2981993097 workType "article" @default.